Prion-like protein Doppel expression is not modified in scrapie-infected cells and in the brains of patients with Creutzfeldt–Jakob disease  by Peoc’h, K et al.
Prion-like protein Doppel expression is not modi¢ed in scrapie-infected
cells and in the brains of patients with Creutzfeldt^Jakob disease
K. Peoc’ha;b, H. Vollandc, A. De Gassartd, P. Beaudrya;b, V. Sazdovitche, M.C. Sorgatof ,
C. Creminonc, J.-L. Laplanchea;b;, S. Lehmannd
aService de Biochimie et Biologie Mole¤culaire, Ho“pital Lariboisie're, 2 Rue A. Pare¤, 75475 Paris, France
bUPRES EA 3621 ‘Biologie des maladies a' prions et re¤gulations cellulaires’, Faculte¤ de Pharmacie, 4 Avenue de l’Observatoire, 75006 Paris, France
cService de Pharmacologie et d’Immunologie, CEA Saclay, 91191 Gif Sur Yvette Cedex, France
dBiologie des Ence¤phalopathies Spongiformes Transmissibles IGH du CNRS, UPR 1142, 141 rue de la Cardonille, 34396 Montpellier Cedex 5, France
eLaboratoire de Neuropathologie R. Escourolle, Groupe hospitalier Pitie¤-Salpe“trie're, INSERM U 360, 47 bd de L’Ho“pital, 75013 Paris, France
fDipartimento di Chimica Biologica, Universita di Padova, 35121 Padova, Italy
Received 28 November 2002; accepted 3 December 2002
First published online 16 January 2003
Edited by Jesus Avila
Abstract Doppel protein has been discovered in prnp knock-
out mouse lines, with overproduction of this protein in the brain
causing ataxia and neurodegeneration. We investigated whether
Doppel expression (i) a¡ected or was a¡ected by the course of
prion propagation in neuroblastoma cells, or (ii) modulated
Creutzfeldt^Jakob disease pathogenesis. No change in Doppel
production was detected in N2a cells, before or after infection.
Transient murine Doppel gene expression had no e¡ect on N2a
viability or PrPSc production. A sensitive immunometric assay
revealed low levels of Doppel in human brain, re£ecting weak
transcription of the corresponding gene. No di¡erence in brain
Doppel levels was observed between Creutzfeldt^Jakob disease
patients and controls, adding further evidence that Doppel is
unlikely to be involved in prion disease pathogenesis.
+ 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Prions cause a group of fatal neurodegenerative diseases,
including Creutzfeldt^Jakob disease (CJD) in humans [1].
The main event in the pathogenesis of these diseases is the
conversion of the cellular prion protein (PrPc), a normal ubiq-
uitous protein encoded by the gene PRNP, to an abnormal
isoform, scrapie prion protein (PrPSc) [1]. PrPc is a glycopro-
tein, about 210 amino acids long when mature; it is present in
large amounts in neurons [2], binds copper with high a⁄nity
[3], and may be involved in cell signalling [4].
Prion infections are post-translational disorders, as PrPSc
accumulates in the brains of infected animals with no change
in PrP mRNA levels [5]. However, prion infections may mod-
ulate the transcription of various genes [6^10].
A new mouse gene, prnd, encoding the PrP-like protein
Doppel (Dpl, for downstream prion protein-like) was recently
discovered 16 kb downstream of prnp [11,12]. The unexpected
overexpression of prnd in two speci¢c lines of prnp knock-out
mice (Prnp0=0, Ngsk, and RcmO lines), led to late-onset ataxia
associated with Purkinje cell degeneration [11,12]. The role of
this protein in conferring this phenotype was con¢rmed in
transgenic PrP0=0 mice overproducing Dpl [13,14]. Further-
more, the ataxic phenotype was corrected by introduction of
a wild-type prnp transgene [15]. This suggests that Dpl and
PrP interact, possibly on the basis of the similarities between
the two proteins. Both proteins are glycosylphosphatidylino-
sitol-anchored, and share 25% C-terminal sequence homology,
resulting in a K-helix-rich folding pattern [11,16,17]. Prnd is
expressed at low levels in the brains of wild-type adult mice,
and transcription levels are highest in the testis in mice, sheep
and cattle [11,18]. In humans, Dpl is expressed in large
amounts in the Sertoli cells, mature spermatozoa and seminal
£uid [19].
Recent studies have investigated the possible modulation of
prion diseases by ectopically produced Dpl in experimentally
infected animals [20]. The in£uence of Dpl in cultured infected
cells and in humans with prion diseases is unknown. We
therefore investigated whether Dpl production a¡ected, or
was a¡ected by, the course of prion propagation in the
chronically infected neuronal cell model, N2a. We then inves-
tigated whether human Dpl (HuDpl) production was modi¢ed
in the brains of patients who died from CJD.
2. Materials and methods
2.1. Antibodies
Monoclonal antibodies (mAbs) were raised against recombinant
human Dpl (rHuDpl 28^152) (rHuDpl); they do not recognize the
mouse protein. Anti-Dpl polyclonal antibody (pAb) DDC39, anti-PrP
mAb 3F4, pAb P45^66 and SAF mixtures have been described else-
where [19,21].
2.2. Construction of a mouse Dpl-encoding plasmid
The open reading frame of the mouse Dpl (MoDpl) gene was am-
pli¢ed by polymerase chain reaction (PCR) from mouse genomic
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DNA (gift of Dr. Andrew Goldsborough, Montpellier, France) using
the following primers: sense 5P-GACCAGGAATTCATGAAGAA-
CCGGCTGGGTACA-3P and antisense 5P-GACCAGGAATTCTT-
ACTTCACAATGAACCAAAC-3P. The puri¢ed PCR product was
digested with EcoRI (New England Biolabs) and ligated into pcDNA3
(Invitrogen). Constructs were veri¢ed by sequencing.
2.3. Cell culture transfection
The N2a#58 clone was chronically infected with the 22L prion
strain as previously described [21]. Where indicated, cells were tran-
siently transfected with Lipofectamine (Invitrogen), according to the
manufacturer’s instructions.
2.4. RT-PCR analysis
Total RNA (5 Wg) extracted from adult 129 SV mouse brain and
testis was reverse-transcribed with M-MLV reverse transcriptase (In-
vitrogen). Equivalent amounts of cDNA were used for prnd study,
using the primers described by Moore et al. ([11]) : DW 189 and
DW 96. Human cDNAs from brain and testis (Clontech, Palo Alto,
CA, USA) were ampli¢ed using primers Dplex1 (forward) 5P-GA-
GGCTCCAGAGGCACACT-3P and Dplex2 (reverse) 5P-CTCGG-
CTCCAAGTCAATGT-3P and L-actin (actb/ACTB) primers ACTB
ex 1 (forward) 5P-CCAGAGCAAGAGAGGCATCC-3P and ACTB
ex 2 (reverse) 5P-GCTGGGGTGTTGAAGGTCTC-3P) under stan-




































Fig. 1. A: Levels of prnd mRNA in control and infected N2a#58 cells and in mouse brain. RT-PCR was performed with the mouse cDNA, us-
ing prnd-speci¢c primers. The results obtained are compared with those obtained with actb primers. B: a: Transient expression of MoDpl in
N2a cells and e¡ect on PrPc and PrPSc production. Dpl and PrP were detected by Western blotting, directly or after digestion by PK, with
pAb DDC39 (Dpl), P45^66 (PrP, PK3) or SAF mixture (PrP, PK+). Where indicated, cells were transiently transfected with a plasmid encod-
ing the murine prnd gene, and analyzed 72 h after transfection. The two bands in the ¢rst and fourth lanes were not speci¢c. Molecular weight
is indicated in kDa. b: Dpl is not detected in the mouse brain by Western blotting. Dpl levels in the brain (90 Wg total protein loaded) and tes-
tis (30 Wg) were investigated by Western blotting with pAb DDC39 (1/10 000). The band observed in the brain lane was not speci¢c. Molecular
weight is indicated in kDa.
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2.5. Cell and tissue extract preparations and Western blotting
Cells were lysed in lysis bu¡er (150 mM NaCl, 0.5% Triton X-100,
0.5% sodium deoxycholate, 20 mM Tris^HCl pH 7.5), centrifuged and
mixed directly with Laemmli bu¡er or treated with proteinase K (PK;
16 Wg/mg total protein; Roche Diagnostic) for 30 min at 37‡C. Di-
gestion was stopped by incubation with Pefabloc (1 mM; Roche Di-
agnostic) for 5 min on ice. The suspension was centrifuged (20 000Ug,
45 min, 4‡C), and pellets were suspended in Laemmli bu¡er.
Brain tissues were obtained from autopsies of 10 sporadic CJD
patients of both sexes, CJD diagnosis was con¢rmed by neuropatho-
logical examination and PrPSc detection in frontal cortex homoge-
nates (either type 1 or 2). No mutations were detected in PRNP.
Thirteen non-CJD patients of both sexes (10 patients with amyotro-
phic lateral sclerosis, one with stroke, one with Alzheimer’s disease,
and one with metabolic encephalopathy) were analyzed for compar-
ison. Testes were obtained at autopsy from non-CJD patients; mouse
brain and testes were obtained from 129 SV mice. Tissues were frozen
and stored at 380‡C until assay. Tissues were homogenized at 4‡C in
lysis bu¡er (10% w/v), centrifuged and protein concentrations were
determined by the BCA technique (Bio-Rad).
For Western blotting, samples were run in 12% polyacrylamide gels
containing sodium dodecyl sulfate and glycine and proteins were de-
tected as previously described [19,21], using the antibodies indicated in
the text.
2.6. Enzymatic immunoassay for HuDpl
The tetrameric form (G4) of acetylcholinesterase (AChE) was co-
valently coupled to mAb anti-Dpl as previously described [22]. Im-
munometric assays were performed with brain homogenates (8 mg/ml
total protein) or rHuDpl (28^152), as previously described [23], with
Dop79 as capture antibody and Dop28-AChE as tracer [23].
2.7. A⁄nity chromatography
BrCN Sepharose 4B was incubated overnight with 3^5 mg Dop28
in 0.1 M carbonate bu¡er, 0.5 M NaCl, pH 8.5. The gel was washed
in carbonate bu¡er, incubated for 2 h in 0.1 M Tris^HCl, pH 8,
washed and resuspended in 0.01% NaN3 in 0.1 M phosphate bu¡er
pH 7.4. We incubated 250 Wl of brain homogenate (8 mg protein/ml)
for 2 h at 4‡C with 50 Wl of a⁄nity gel. The mixture was centrifuged
for 10 min at 15 000Ug and 100 Wl of supernatant was used for
immunometric assay.
3. Results and discussion
We ¢rst investigated the presence of prnd transcripts and
MoDpl in control and chronically infected N2a cells. Prion
propagation in the infected cells was assessed by detecting
PrPSc by Western blotting. Prnd transcripts were faintly de-
tected by RT-PCR in both cases, with no evidence of marked
up- or down-regulation following infection (Fig. 1A). The
level of prnd transcription in the N2a cell line was similar to
that in mouse brain, and considerably lower than that in the
testis (Fig. 1A) [11].
We used wild-type and infected N2a lysates for Western
blotting, to determine whether prnd mRNA was translated
into detectable amounts of MoDpl (Fig. 1B,a). MoDpl was
detected in neither normal nor infected cells, but was readily
detected in the testis, as previously reported (Fig. 1B,b) [16].
No MoDpl was detected in mouse brain. As the detection
limit for Western blotting for rHuDpl was estimated to be
about 300 ng (data not shown), the method may not have
been sensitive enough to detect small amounts of the protein
in these cells. However, no signi¢cant change in prnd expres-
sion was observed during infection of the N2a cell line with
the 22L scrapie strain. These ex vivo results are similar to the
results obtained in vivo in mice injected intracerebrally with
scrapie, in which prion infection does not a¡ect prnd expres-
sion levels in the central nervous system [20].
We then investigated whether the ectopic production of
MoDpl a¡ected the course of prion propagation in N2a cells.
We carried out transient transfection experiments with the
murine prnd gene (Fig. 1B,a). No change in cell morphology
or growth rate was observed following MoDpl production.
MoDpl synthesis did not a¡ect level of PrPc or PrPSc produc-
tion. These data are consistent with a recent report [14]
indicating that the level of prnd expression in the brain does
not a¡ect the incubation period, vacuolar pathology or the
amount or distribution of PrPSc deposition in the brains of
mice intracerebrally inoculated with prions. Finally, no PK-
resistant form of MoDpl was generated, indicating that, de-
spite the structural similarity of the two proteins, PrPSc did
not impose its conformational imprinting on Dpl.
Similar conclusions concerning the role of Dpl in prion
pathogenesis were drawn from experiments involving infected
neuroblastoma cells and experimentally infected mice [14]. We
nonetheless extended the study to a spontaneous human prion
disease, sporadic CJD. Genetic variations in the coding se-
quence of PRND are not associated with susceptibility to or
the expression of sporadic CJD [24]. However, this lack of
genetic association did not rule out the possibility of changes
in HuDpl production in the brains of patients with the dis-
ease.
We found that PRND was transcribed less strongly in the
brains of non-CJD individuals than in the testes (Fig. 2A).
HuDpl was not detected by Western blotting in the control
(Fig. 2B) or in CJD brains, even after immunoprecipitation
(data not shown). We therefore designed a speci¢c immuno-
assay, to increase the sensitivity of detection. The two-site
immunometric assay was developed with a combination of
two mAbs ^ Dop79 and Dop28 ^ which provided the most
sensitive detection (Fig. 3A), using rHuDpl as the standard.
The detection limit of the assay was below 10 pg/ml.
Brain homogenates from ¢ve CJD and ¢ve non-CJD pa-
tients were assayed for HuDpl before and after a⁄nity chro-
matography with mAb Dop28. The absorbance obtained with
untreated homogenates was strongly decreased by this chro-
matography step, narrowing the blank value (Fig. 3A), indi-
cating that HuDpl was speci¢cally detected by the immuno-
metric test. The amount of HuDpl in brain homogenates was
estimated to be around 15^50 ng/g total protein, using
rHuDpl as a standard. This is about one thousandth the
amount present in the testis (35^50 Wg/g) or seminal plasma
(7^15 Wg/g) [19]. We therefore determined HuDpl levels di-

















Fig. 2. A: PRND transcripts are detected in human brain. RT-PCR
on cDNA from human organs was carried out using ACTB- and
PRND-speci¢c primers. B: Dpl is not detected in the human brain
by Western blotting. HuDpl levels in the brain (90 Wg total protein
loaded) and testis (8 Wg) were investigated by Western blotting with
pAb DDC39 (1/10 000). Molecular weight is indicated in kDa.
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CJD patients (Fig. 3B). No signi¢cant di¡erence was observed
between CJD patients (median optical density (OD): 0.190;
range: 0.120^0.269) and non-CJD patients (median OD:
0.221; range: 0.083^0.430; Kolmogorov^Smirno¡ test: P=
0.27). PRNP codon 129 genotypes and PrPSc types did not
seem to a¡ect HuDpl levels in sporadic CJD, but this ¢nding
is based on limited observation. Our results thus suggested
that HuDpl production was una¡ected in the brain of spo-
radic CJD patients. For comparison, PrPc is present at a con-
centration of about 1^10 Wg/g total protein in humans
(J. Grassi, personal communication) and sheep [25]. There-
fore, the abundance of PrPc in the brain is more than 1000
times greater than that of Dpl, precluding toxic e¡ects of the
protein in the brain, as observed in PrP0=0 mice overproducing
Dpl [13,14].
In conclusion, weak transcription of the PRND gene in
human brain led to very low levels of HuDpl, detected only
with a highly sensitive immunometric test. Neither mRNA nor
Dpl levels appeared to be modi¢ed by prion infection in
chronically infected N2a cells or in sporadic CJD. These
data, and those obtained in experimentally infected animals
[20], indicate that Dpl is probably not involved in prion dis-
ease pathogenesis, in the central nervous system at least. How-
ever, the putative interaction between Dpl and PrPc may pro-
vide clues as to the enigmatic function of PrPc. Dpl is thought
to be involved in male fertility [19,26] and the new immuno-
assay presented here opens up possibilities for the sensitive
detection of HuDpl in human £uids and tissues.
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